You are here
Family Bank: Cordlife Group Limited
Incorporated in May 2001, Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group"), is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, Malaysia, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and other genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech (Hong Kong) Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam.
Labs and Locations
Cordlife Group Limited
1 Yishun Industrial Street 1 #06-01/09,
A'Posh Bizhub Singapore 768160
Inhabiting a distinctive niche in the healthcare industry, the Group is one of the foremost private cord blood banks to have gained a solid foothold in Asia. In the last 17 years, Cordlife has dedicated its undertakings to achieve market leadership in the industry. Having built a distinguished brand name, the Group continues to strive for excellence by means of support from its experienced management team and dynamic key executives, along with its quality product and service offerings. Cordlife believes the Group has in place a strong foundation for future expansion.
Quality and customer focus are amongst some of the cornerstones of Cordlife. The Group's stem cell processing and storage facilities in Singapore, Hong Kong, India, the Philippines and Malaysia are accredited by AABB, the organisation behind the world's gold standard for cord blood banking. In addition, Cordlife Singapore is accredited by FACT, another world-class accreditation body for cord blood banks globally. This makes Cordlife Singapore one of just six cord blood banks in the world to be accredited by both AABB and FACT simultaneously. In the area of clinical diagnostics, Cordlife India, HealthBaby and Hong Kong Screening Centre are accredited by the College of American Pathologists (“CAP”). These quality achievements underpin the Group’s commitment to providing the highest service quality for clients.
The kit contains a closed system blood bag (brand JMS) that is pre-loaded with the anti-coagulant CPDA-1. The kit also provides the disinfectant Povidone-iodine.
The collection kit is constructed with thermal insulation and validated to maintain room temperature for up to 48 hours during transportation back to the laboratory.
Cordlife provides dedicated staff to pick up the cord blood sample from Singapore hospitals upon notification.
Stem cells are separated from the cord blood using the fully automated and closed Sepax system from Biosafe. The final component is the buffy coat layer of the blood, which holds both white cells and stem cells.
Parents are provided with a report describing test results for the buffy coat holding white cells and stem cells including total nucleated cells (TNC), post processing sterility, viable CD34+ counts, as well as maternal blood infectious disease results.
Final cord blood storage is in 25 ml blood (cryo) bag encased in an overwrap. Blood samples are kept in a quarantine freezer, then moved to long term freezer after they pass testing. Stem cells are stored in the vapour phase of cryogenic nitrogen.
Licensing & Accreditation
- Certified by Singapore Ministry of Health
- Accredited by AABB
- Accredited by FACT
- Cordlife Singapore is the first bank in Southeast Asia and one of the six cord blood banks in the world, to achieve dual AABB & FACT accreditation
The Group has successfully released 41 cord blood units to support stem cell transplantation and therapeutic infusions.
Cordlife clients will be covered by a program known as the Cordlife Care360 – a holistic program aimed to safeguard our client and their family.
1) Cordlife provides the coverage of possible pregnancy and childbirth complications*.
2) Cordlife will cover future storage payments if death or total permanent disability* occurs to either biological parent of Child during the contractual storage period.
3) Cordlife assures clients a cord blood unit of suitable match or US$25,000 to defray medical costs if the cord blood loses its viability at point of transplant*.
4) Cordlife will cover the cost for additional tests required in the event of a transplant* - matching (HLA resolution test) and viability (CFU assay).
5) Cordlife has taken additional insurance coverage, to safeguard client and their family from financial loss resulting from direct malpractice*.
* Terms and Conditions apply
For more information, please submit a price plan enquiry
Cordlife has an exclusive license on patented technology to harvest and store two types of stem cells from the lining of the umbilical cord. This cord lining contains both Epithelial Stem Cells (EpSC) and Mesenchymal Stem Cells (MSC).